Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Jutant (Le Kremlin-Bicêtre, France), L. Tu (Le Kremlin-Bicêtre, France), B. Le Vely (Le Kremlin-Bicêtre, France), R. Thuillet (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), C. Guignabert (Le Kremlin-Bicêtre, France), A. Huertas (Le Kremlin-Bicêtre, France). Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?. 3557

Member's Comments

No comment yet.

Related content which might interest you: Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling? Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Leptin signalling system as a target for pulmonary arterial hypertension therapy Source: Eur Respir J 2015; 45: 1066-1080 Year: 2015 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Roundabout (Robo) receptors on pulmonary artery endothelial cells: Implications for pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research Source: Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017 Year: 2017 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020 Year: 2021 Activation of AMPK inhibits pulmonary arterial remodeling Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Stabilised ferroportin activity affects pulmonary vascular cells responses: implications for pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018